About Us

 

Our Story

SanoLibio is an internationally recognized biomedical technology innovator. Having understood that it is firstly technology that enables advancement, we have opened a new window with our proprietary automated cell separation platform into rare blood cell analysis which is seen as the next generation of liquid biopsy diagnostics potentially managing many health issues of our times, including cancer, myocardial infarction, diabetes and many more. Our unique rare cell enrichment platform called “Walderbach” is one of the very few worldwide to allow comprehensive ultra-rare cell enrichment and detection which is a crucial detail for the understanding of disease evolution and delineation that ultimately leads to better health care.

Latest News

Newsfeed

Announcement of a new publication

3.10.2022 – We are dedicated to unearth the composition of the rare cell population in health and in disease with the support of SanoLibio technology. Our latest discovery is a …

Newsfeed

SanoLibio in Use

24.05.2022 – SanoLibio announces the commencement of a clinical trial conducted by its partner company Premise Biosystems Co., Ltd. (Thailand) in collaboration with Rama Thibodi Hospital in Bangkok for the …

Contact Us

Representation in Thailand

SanoLibio Co,. Ltd.

99/59 Moo 8 Racha Thewa Bang Phli
Samut Prakan 10540, Thailand

Management (Thailand)
Dr. Stefan Schreier
Usa Suteelaxnaporn
T: +66 838904716
E: info@sanolibio.com
Company registration:
Tax ID:0115562031174

Representation in Germany

SanoLiBio GmbH

Walpurgisstraße 4
81677 Munich, Germany

Management (Germany)
Dr. Stefan Schreier
Dipl.-BioIng. Timo Peter
T: +49 172 888 9848
E: info@sanolibio.com

Company registration:

Registration court: Munich
Registration number: HRB 233644
Tax ID: 143/177/81335
USt-ID: DE312531649
Content Responsibility: Stefan Schreier